Spectral Ai, Inc. (MDAIW) — SEC Filings
Spectral Ai, Inc. (MDAIW) — 45 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 29 8-K, 5 10-Q, 2 DEF 14A.
View Spectral Ai, Inc. on SEC EDGAR
Overview
Spectral Ai, Inc. (MDAIW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Spectral AI, Inc. (MDAIW) reported a significant decrease in research and development revenue for the three months ended September 30, 2025, falling to $3.792 million from $8.173 million in the prior year, a 53.6% decline. For the nine months ended September 30, 2025, revenue decreased to $15.564 mi
Sentiment Summary
Across 45 filings, the sentiment breakdown is: 3 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Spectral Ai, Inc. is neutral.
Filing Type Overview
Spectral Ai, Inc. (MDAIW) has filed 5 10-Q, 29 8-K, 2 DEF 14A, 1 10-K, 2 SC 13G/A, 2 S-1, 2 SC 13D/A, 1 SC 13G, 1 S-1/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (45)
Risk Profile
Risk Assessment: Of MDAIW's 41 recent filings, 3 were flagged as high-risk, 14 as medium-risk, and 24 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $15.564M |
| Net Income | $(8.623)M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $10.495M |
| Operating Margin | N/A |
| Total Assets | $15.300M |
| Total Debt | $23.503M |
Key Executives
- David J. Miller
- Dr. David L. Smith
- Mr. Robert J. Smith
- Peter M. Carlson
- DiMaio John Michael
- C. Robert Bruner
- Erich Spangenberg
- United Kingdom
- December 31, 2023
- Wensheng Fan
Industry Context
Spectral AI operates in the medical device sector, specifically focusing on AI-powered diagnostic solutions. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies often rely on government grants and strategic partnerships for funding clinical validation and market entry. The competitive landscape includes established medical device manufacturers and emerging tech companies, all vying for market share and regulatory approvals.
Top Tags
corporate-governance (8) · financial-reporting (5) · Spectral AI (5) · company-update (4) · exhibits (4) · financials (4) · filing (4) · 10-Q (4) · material-agreement (3) · equity-sale (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Research and development revenue (Q3 2025) | $3.792M | Decreased from $8.173M in Q3 2024, a 53.6% decline. |
| Research and development revenue (9 months ended Sep 30, 2025) | $15.564M | Decreased from $21.977M in the prior year, a 29.2% reduction. |
| Net loss (Q3 2025) | $(3.552)M | Widened from $(1.504)M in Q3 2024. |
| Net loss (9 months ended Sep 30, 2025) | $(8.623)M | Widened from $(7.573)M in the prior year. |
| Cash (Sep 30, 2025) | $10.495M | Increased from $5.157M at Dec 31, 2024. |
| Net cash provided by financing activities (9 months ended Sep 30, 2025) | $12.670M | Primarily from notes payable and warrant exercises. |
| BARDA contract funding | $150.0M | Total potential funding, with an initial award of $54.9M. |
| Shares of Common Stock outstanding (Nov 11, 2025) | 30,688,895 | Indicates dilution from previous periods. |
| Accumulated deficit (Sep 30, 2025) | $(56.852)M | Increased from $(48.229)M at Dec 31, 2024. |
| Proceeds from warrant exercises (9 months ended Sep 30, 2025) | $1,992 | Contributed to cash increase. |
| SEC File Number | 001-40058 | Identifier for the company's filings |
| EIN | 85-3987148 | Employer Identification Number |
| Par Value per Share | 0.0001 | Common Stock Par Value |
| Exercise Price per Share | 2.75 | Redeemable Warrants |
| IRS Employer Identification No. | 85-3987148 | Company's tax identification number. |
Forward-Looking Statements
- {"claim":"Spectral AI, Inc.'s stock price will remain stable in the short term due to the lack of new material information in this filing.","entity":"Spectral AI, Inc.","targetDate":"2024-03-12","confidence":"high"}
- {"claim":"Other institutional investors may re-evaluate their positions in Spectral AI, Inc. following Octopus Investments Ltd.'s reduced stake.","entity":"Spectral AI, Inc.","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Spectral Ai, Inc. (MDAIW)?
Spectral Ai, Inc. has 45 recent SEC filings from Jan 2024 to Nov 2025, including 29 8-K, 5 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MDAIW filings?
Across 45 filings, the sentiment breakdown is: 3 bearish, 41 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Spectral Ai, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Spectral Ai, Inc. (MDAIW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Spectral Ai, Inc.?
Key financial highlights from Spectral Ai, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MDAIW?
The investment thesis for MDAIW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Spectral Ai, Inc.?
Key executives identified across Spectral Ai, Inc.'s filings include David J. Miller, Dr. David L. Smith, Mr. Robert J. Smith, Peter M. Carlson, DiMaio John Michael and 5 others.
What are the main risk factors for Spectral Ai, Inc. stock?
Of MDAIW's 41 assessed filings, 3 were flagged high-risk, 14 medium-risk, and 24 low-risk.
What are recent predictions and forward guidance from Spectral Ai, Inc.?
Recent forward-looking statements from Spectral Ai, Inc. include guidance on {"claim":"Spectral AI, Inc.'s stock price will remain stable in the short term due to the lack of new material informati and 1 other predictions.